statnews.com — Scour · Scour

statnews.com

267 posts in the last 30 days

STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it

statnews.com·33m

STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval

statnews.com·51m

STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director

statnews.com·1h

STAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS

statnews.com·2h

STAT+: Trump’s plan to give seniors cheaper obesity drugs in Medicare hits a snag

statnews.com·3h

Flu vaccine no longer mandated for U.S. troops, defense secretary says

statnews.com·6h

STAT+: UnitedHealth earnings beat expectations in the first quarter, but hurdles persist

statnews.com·7h

STAT+: RFK Jr. to face four GOP doctors at Senate hearings

statnews.com·8h

Opinion: STAT+: I’m an expert on presidential health. The 25th Amendment is not an option for removing Trump

statnews.com·8h

A criminal sentence for OxyContin maker Purdue Pharma clears the way for completing its settlement

statnews.com·8h

STAT+: CMS to ask every state for new audits of health care providers

statnews.com·9h

STAT+: Kelonia Therapeutics’ road from floundering to $3 billion

statnews.com·9h

STAT+: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more

statnews.com·10h

This CDC conference was always open to the public. Until now.

statnews.com·10h

STAT+: Kennedy hints at coming breakthrough device announcement

statnews.com·11h

STAT+: Tortugas Neuroscience launches with hopes to develop drugs for brain disorders, other conditions

statnews.com·12h

STAT+: BioAge says experimental pill aimed at reducing heart risks significantly reduced inflammation

statnews.com·12h

Opinion: The U.S. health care system is built around looking backward

statnews.com·15h

Opinion: What happens when a chief executive loses executive functions?

statnews.com·15h

STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem

statnews.com·1d

Loading more...